ICER On Asthma Biologics: 50%-79% Price Discounts Needed To Meet Value Assessment Metrics

The independent value assessment organization’s draft assessment found that the prices for all five marketed biologics for severe asthma – Xolair, Nucala, Cinqair, Fasenra and Dupixent – far exceed standard cost-effectiveness thresholds.